文献速递妇科

超声引导高强度聚焦超声治疗子宫腺肌病和子宫肌瘤后抗苗勒管激素水平变化作为卵巢储备生物标志物

Changes in anti-müllerian hormone levels as a biomarker for ovarian reserve after ultrasound-guided high-intensity focused ultrasound treatment of adenomyosis and uterine fibroid.
PubMed 文献 · BJOG · 2017-01-01

这项前瞻性研究纳入79例子宫肌瘤和子宫腺肌病患者,2014年1月至12月接受超声引导高强度聚焦超声消融,比较治疗前与治疗后6个月抗苗勒管激素水平。治疗前为2.11±2.66 μg/l,治疗后6个月为1.84±2.57 μg/l,两者无显著差异(P>0.05)。结论认为该消融有效且不影响卵巢储备。

要点

  • 治疗前与治疗后6个月抗苗勒管激素分别为2.11±2.66与1.84±2.57 μg/l,无显著差异(P>0.05)。
  • 研究纳入79例子宫肌瘤和子宫腺肌病患者,接受超声引导高强度聚焦超声消融。
  • 结论认为该消融对子宫肌瘤和子宫腺肌病有效且不影响卵巢储备。

核心结论

  • 超声引导高强度聚焦超声消融治疗子宫肌瘤和子宫腺肌病有效,且不影响卵巢储备。

研究设计与样本

  • 前瞻性研究,纳入2014年1月至2014年12月间79例符合纳入标准的有症状子宫肌瘤和子宫腺肌病患者,均接受超声引导高强度聚焦超声消融。
  • 每例患者在治疗前、治疗后及治疗后6个月和12个月接受T2加权MRI和钆增强T1加权MRI检查,评估症状严重程度评分、子宫肌瘤症状生活质量问卷子量表及治疗体积缩小。
  • 比较治疗前与治疗后6个月抗苗勒管激素水平,以判断消融是否影响卵巢储备。

主要发现

  • 高强度聚焦超声治疗时间(均值±标准差)为73.5±25.6分钟,消融时间为9994.7±386.8秒,治疗能量为364713.8±156350.7焦耳。
  • 治疗前与治疗后6个月抗苗勒管激素水平分别为2.11±2.66 μg/l与1.84±2.57 μg/l,两个时间点间无显著差异(P>0.05)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the changes in antimüllerian hormone (AMH) levels after ablation for symptomatic uterine fibroids and adenomyosis using ultrasound-guided high-intensity focused ultrasound (USgHIFU). DESIGN: A prospective study. SETTING: Gynaecological department in multiple hospitals in South Korea. POPULATION: Patients with uterus fibroids and adenomyosis. METHODS: Seventy-nine women with symptomatic uterine fibroids and adenomyosis who met the inclusion criteria were enrolled in our study between January 2014 and December 2014. All patients underwent USgHIFU ablations. Each patient was examined before and after treatment, and at 6 and 12 months after treatment by T2-weighted MRI imaging (T2WI) and T1-weighted MRI imaging (T1WI) with gadolinium injection. Symptom severity scores (SSS), Uterine Fibroid Symptom Quality of Life (UFS-QOL) questionnaire subscales, and reductions of treated volume were assessed. AMH levels before and 6 months after HIFU ablation were compared to determine whether USgHIFU ablation affected ovarian reserve. MAIN OUTCOME MEASURES: HIFU treatment did not affect the ovarian function. RESULTS: HIFU treatment time (mean ± standard deviation), HIFU ablation time, and treatment energy were 73.5 ± 25.6 minutes, 9994.7 ± 386.8 seconds, and 364 713.8 ± 156 350.7 Joules, respectively. AMH levels before and 6 months after HIFU ablation were 2.11 ± 2.66 and 1.84 ± 2.57 μg/l, respectively. There was no significant difference in AMH level between the two time points (P > 0.05). CONCLUSIONS: USgHIFU ablation for uterine fibroid and adenomyosis was effective without affecting ovarian reserve. TWEETABLE ABSTRACT: HIFU ablation is a safe and effective treatment for patients with uterine fibroids and adenomyosis that does not affect ovarian function.

来源:BJOG,查看原文。版权归原作者所有。

引用

  1. Lee JS, Hong GY, Lee KH, et al. Changes in anti-müllerian hormone levels as a biomarker for ovarian reserve after ultrasound-guided high-intensity focused ultrasound treatment of adenomyosis and uterine fibroid. BJOG. 2017. PMID: 28856867. doi:10.1111/1471-0528.14739

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。